| Project/Area Number |
17016051
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research on Priority Areas
|
| Allocation Type | Single-year Grants |
|---|
| Review Section |
Biological Sciences
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
SONE Saburo The University of Tokushima, 大学院・ヘルスバイオサイエンス研究部, 教授 (40145024)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YANO Seiji 金沢大学, がん研究所, 教授 (30294672)
NISHIOKA Yasuhiko 徳島大学, 大学院・ヘルスバイオサイエンス研究部, 准教授 (70274199)
KAKIUCHI Soji 徳島大学, 大学院・ヘルスバイオサイエンス研究部, 准教授 (50380100)
GOTO Hisatsugu 徳島大学, 大学院・ヘルスバイオサイエンス研究部, 講師 (00437641)
HANIBUCHI Masaki 徳島大学, 医学部・歯学部附属病院, 講師 (80335794)
|
|---|
| Project Period (FY) |
2005 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥45,700,000 (Direct Cost: ¥45,700,000)
Fiscal Year 2009: ¥8,600,000 (Direct Cost: ¥8,600,000)
Fiscal Year 2008: ¥8,600,000 (Direct Cost: ¥8,600,000)
Fiscal Year 2007: ¥9,500,000 (Direct Cost: ¥9,500,000)
Fiscal Year 2006: ¥9,500,000 (Direct Cost: ¥9,500,000)
Fiscal Year 2005: ¥9,500,000 (Direct Cost: ¥9,500,000)
|
|---|
| Keywords | 骨転移 / 破骨細胞 / 血管新生 / 樹状細胞 / 可溶性VEGF受容体 / EGFR阻害薬 / 薬剤耐性 / 肝細胞増殖因子 / 抗HM1.24抗原 / HGF / マルチキナーゼ阻害薬 / 胸膜中皮腫 / organotropism / 抗PTHrP抗体 / ビスフォスフォネート / HM1.24抗原 / ADCC / 耐性 / ゲフィチニブ / マイクロアレイ / プロテオーム解析 / 脳転移 / 癌性胸水 / VEGF / 蛍光気管支鏡 / 肺癌 / 多臓器転移 / MYO18B / PTHrP / Src / CD9 |
|---|
| Research Abstract |
We focused on cancer microenvironment and found that drugs which suppressed osteoclast-function inhibited lung cancer bone metastasis. The factor selectively expressed in bone metastatic lesions acted as an inhibitor of multiple organ metastasis. Dendritic cells produced soluble VEGF receptor 1, suppressed angiogenesis, and thereby inhibited lung cancer progression. Humanized anti-HM1.24 antibody inhibited growth of HM1.24 expressing lung cancer cells. Hepatocyte growth factor (HGF) induced resistance to EGFR tyrosine kinase inhibitors, indicating that HGF may be important target for overcoming the resistance in lung cancer.
|
